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Tubular Cardiac Tissues Derived 
from Human Induced Pluripotent 
Stem Cells Generate Pulse Pressure 
In Vivo
Hiroyoshi Seta1,2, Katsuhisa Matsuura2,3, Hidekazu Sekine2, Kenji Yamazaki1 & 
Tatsuya Shimizu2
Human induced pluripotent stem (iPS) cell-derived cardiac cells provide the possibility to fabricate 
cardiac tissues for transplantation. However, it remains unclear human bioengineered cardiac tissues 
function as a functional pump in vivo. Human iPS cells induced to cardiomyocytes in suspension were 
cultured on temperature-responsive dishes to fabricate cardiac cell sheets. Two pairs of triple-layered 
sheets were transplanted to wrap around the inferior vena cava (IVC) of nude rats. At 4 weeks after 
transplantation, inner pressure changes in the IVC were synchronized with electrical activations of 
the graft. Under 80 pulses per minute electrical stimulation, the inner pressure changes at 8 weeks 
increased to 9.1 ± 3.2 mmHg, which were accompanied by increases in the baseline inner pressure of 
the IVC. Immunohistochemical analysis revealed that 0.5-mm-thick cardiac troponin T-positive cardiac 
tissues, which contained abundant human mitochondria, were clearly engrafted lamellar around the 
IVC and surrounded by von Willebrand factor-positive capillary vessels. The mRNA expression of several 
contractile proteins in cardiac tissues at 8 weeks in vivo was significantly upregulated compared with 
those at 4 weeks. We succeeded in generating pulse pressure by tubular human cardiac tissues in vivo. 
This technology might lead to the development of a bioengineered heart assist pump.
Regenerative medicine is expected to be a promising strategy for patients with impaired tissue/organ functions. 
The integration of stem cell biology with tissue engineering technologies, including cell sheet technology, has 
already realized regenerative therapy in some areas1–3. Current cell therapy using somatic stem cells has improved 
cardiac functions through mainly paracrine effects such as promotion of angiogenesis. Moreover, the recent 
advancement of reprogramming technologies4 has enabled fabrication of human cardiac tissues in vitro5 and 
in vivo6, which may lead to the development of pulsatile tissues to support circulation.
The development of a circulatory support apparatus is a major challenge to compensate for impaired circu-
lation due to severe heart diseases. Left ventricular assist devices are widely used for patients with severe heart 
failure due to various ventricular dysfunction, which have decreased the mortality7. Circulatory support is also 
necessary for patients with pulmonary hypertension owing to univentricular heart disease. However, some issues 
mainly due to the usage of artificial materials including infection, thrombosis and bleeding remain unresolved. 
Therefore, the development of pulsatile bioengineered tissues capable of assisting systemic and pulmonary circu-
lation may provide us with some cues. We previously reported that tubular tissues fabricated using cell sheets of 
neonatal rat cardiomyocytes exhibited measurable inner pressure changes evoked by tube contraction in vitro8. 
Furthermore, transplantation of rat cardiac cell sheets around the rat abdominal aorta led to inner pressure 
changes of about 6 mmHg according to their contraction when the myocardial tubes were clamped to distinguish 
the graft-mediated pulse pressure changes from host pulse pressure9. The transplanted cardiac tissues around 
aorta are exposed to the stretch owing to host pulse pressure, which might lead to promote cardiomyocyte matu-
ration and better function. Conversely, the transplanted cardiac tissues around venous system, the possible case 
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for patients with Fontan operation against univentricular heart disease, are not exposed to the stretch owing 
to pulse pressure. Therefore, it is necessary to elucidate the function and maturation status of bioengineered 
pulsatile human tubular cardiac tissues transplanted around venous system. Furthermore, it remains unclear 
whether bioengineered tubular cardiac tissues have some fundamental properties as a pulsatile pump such as an 
impulse-conduction system and contraction responses against pressure load in vivo.
In the present study, we fabricated human tubular cardiac tissues derived from induced pluripotent stem (iPS) 
cells around the rat inferior vena cava (IVC). Cell sheet-based human tubular cardiac tissues exhibited inner 
pressure changes according to their pulsation when transplanted around the rat IVC. Transplanted cardiac tissues 
were engrafted and matured over time in vivo.
Results
Characteristics of human cardiac cell sheets. First, we attempted to enrich cardiomyocytes in cell 
sheets to achieve the functional outcomes and prevent tumor formation after transplantation. Using human iPS 
cells that expressed a puromycin-resistance gene under the control of the mouse α -myosin heavy chain (α -MHC) 
promoter, puromycin treatment after cardiac differentiation significantly increased the percentage of cardiomyo-
cytes from 57.9 ± 15.3% to 91.2 ± 8.3% (Fig. 1a–c). Cardiac cell sheets were mainly composed of cardiomyocytes 
and partially non-cardiomyocytes including vimentin-positive fibroblasts and CD31-positive endothelial cells 
(Fig. 1d,e).
Transplantation of cardiac cell sheets around the IVC. On days 27–30 of cardiac induction, mon-
olayer cardiac cell sheets were detached by lowering the culture temperature (Fig. 2a). To fabricate tubular car-
diac tissues, we created two pairs of triple-layered cardiac cell sheets in vitro and transplanted these cell sheets 
by wrapping them around the IVC of nude rats (Fig. 2b–d). At 2 weeks after transplantation, a low density area 
around the IVC in 10 of 13 transplanted rats was clearly observed by echography. The thickness of this area was 
maintained over 600 μ m until 8 weeks (2 weeks: 723 ± 140 μ m, 4 weeks: 721 ± 150 μ m, 8 weeks: 610 ± 111 μ m, 2 
weeks vs 4 weeks: p = 0.97. 2 weeks vs 8 weeks: p < 0.05. 4 weeks vs 8 weeks: p < 0.05.) (Fig. 2e,f). Spontaneous 
beating of transplanted cardiac tissues was also observed from 2 or 3 weeks after transplantation by echography 
(Supplementary Video 1,2) and macroscopically (Supplementary Video 3) in all rats which showed a low density 
area around the IVC. The beating was clearly independent of host artery pulsation and maintained at least until 
8 weeks.
Consistent with the results of echographic analysis, immunohistochemical analysis revealed that the thickness 
of the transplanted tissues was > 500 μ m, and no tumor formation was observed (Fig. 3a). Cardiac troponin T 
(cTnT)-positive cardiomyocytes were clearly engrafted around the IVC, and connexin 43 expression was observed 
in the graft area (Fig. 3b,c). Transplanted cardiac tissues contained microvessels expressing von Willebrand fac-
tor (vWF) (Fig. 3d) and interstitial cells expressing vimentin and type 1 collagen (Supplementary Fig. 1). As 
shown in Supplementary Fig. 2, small amount of vWF-positive cells that co-expressed human mitochondria were 
observed. However, many of vWF-positive cells were negative for human mitochondria. These findings suggest 
that CD31-positive endothelial cells in cardiac cell sheets in vitro might slightly contribute to the microvascular 
networks in graft tissues, but the microvascular networks in the graft tissues are mainly derived from host rat. 
Because it is well known that cardiomyocytes contain many mitochondria, human mitochondria were abundant 
in cTnT-positive cardiomyocytes and less present in cTnT-negative interstitial cells (Fig. 3e). These results sug-
gested that human iPS cell-derived cardiac cell sheets were engrafted around the IVC.
Physiological functions of pulsatile tubular tissues. We examined the physiological functions of 
transplanted cardiac tissues (Fig. 4). Consistent with the observation that transplanted tissues showed spontane-
ous beatings, graft tissue-derived electric potentials, which were independent of host heart-derived electric poten-
tials, were observed. The spontaneous graft pulse rate was 54 ± 6 pulses per minute (ppm) at 4 weeks (47–60, 
n = 6) and 58 ± 22 ppm at 8 weeks (30–78, n = 4), respectively. When we attempted to record the inner pressure 
changes in the IVC according to graft spontaneous pulsation, slight inner pressure changes were observed at 
both 4 weeks (4 of 6 rats (0–0.19 mmHg, median: 0.05 mmHg), n = 6) and 8 weeks (4 of 4 rats (0.09–1.06 mmHg, 
median: 0.27 mmHg), n = 4) (Fig. 5a,b). There was no significant difference in inner pressure changes between 4 
weeks and 8 weeks (p = 0.08). However, when the basal pressure of the IVC was increased to around 10 mmHg 
by clamping the proximal and distal region of the IVC to close lumen, the changes of inner pressure were clearly 
observed (Fig. 5c,d). Graft pulsation followed electrical stimulation until 120 ppm. Subsequently, the relation-
ship between the inner pressure changes and basal inner pressure in the IVC was elucidated at 4 and 8 weeks 
after transplantation under 80 ppm electrical stimulation. Interestingly, when the basal inner pressure levels of 
the IVC were increased, graft pulsation-mediated inner pressure changes were also increased accordingly to a 
certain extent, but the excess increase in the basal inner pressure levels attenuated the graft pulsation-mediated 
inner pressure changes (Fig. 5e,f). There was no significant difference in the maximum inner pressure changes in 
clamping conditions between 4 weeks (6.3 ± 1.6 mmHg, n = 4) and 8 weeks (9.1 ± 3.2 mmHg, n = 3) (p = 0.44) 
(Fig. 5g).
Cardiomyocyte maturation in vivo. Our previous report showed that the in vivo environment promoted 
the maturation of iPS cell-derived from cardiomyocytes compared with in vitro conditions in terms of myofibril 
density and the sarcoplasmic reticulum in electron microscopic analysis6. Consistent with these observations, 
the mRNA expression of contractile proteins, such as MYL7, MYH7, TNNT2, and RYR2, a ryanodine receptor, 
was significantly upregulated at 4 weeks in vivo compared with that in cardiac tissues cultured for 4 weeks in vitro 
(Fig. 6). The expression of MYL2 and MYH6 together with MYL7, MYH7, TNNT2 and RYR2 was remarkably 
upregulated in cardiac tissues at 8 weeks in vivo compared with cardiac tissues at 4 weeks in vivo.
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Because continuous stretching has been reported to induce maturation of human pluripotent stem 
cell-derived cardiomyocytes10, we next examined the contribution of continuous stretching on cardiomyocyte 
maturation by comparing the cardiac gene expression between cardiac tissues transplanted around the IVC and 
abdominal aorta. In both case, the cardiomyocytes in the transplanted cardiac tissues were exposed to continuous 
active stretching based on their own beating rate, while the cardiac tissues around the abdominal aorta would be 
exposed to more frequent and passive stretching based on host heart-derived pulsation (Supplementary Video 4, 
Supplementary Fig. 3). However, the mRNA expression of cardiac contractile proteins as well as RYR2 in cardiac 
tissues around the aorta was comparable to that in cardiac tissues around the IVC.
Discussion
The present study demonstrated that human cardiac tissues transplanted around the IVC showed physiological 
inner pressure changes according to their pulsation. Transplanted cardiac tissues were engrafted at least until 8 
Figure 1. Preparation of human cardiac cell sheets. (a) Schematic illustration of the culture process including 
cardiac differentiation, cardiomyocyte purification, and cell sheet fabrication. (b,c) Flow cytometric analysis 
of cells on days 21 and 27 of differentiation. (b) Representative images of flow cytometry analysis. (c) The 
percentage of cardiac troponin T (cTnT)-positive cells was calculated and shown in the graph (n = 5). *p < 0.05. 
(d,e) High content confocal image analysis of cells in cardiac cell sheets (day 27). Nuclei were stained with 
Hoechst 33258. (d) Vimentin (green) expression in cTnT-positive cells (red). Bars, 100 μ m. (e) CD31 (green) 
expression in cTnT-positive cells (red). Bars, 200 μ m. All data are represented as means ± SD.
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weeks and well matured in vivo. This model will lead to the development of bioengineered human heart assist 
pump in future clinical situation.
The replacement of injured and fibrotic tissues, due to mainly myocardial infarction, with bioengineered pul-
satile cardiac tissues is expected to be useful to ameliorate cardiac dysfunction and subsequently improves QOL 
and decreases the mortality of patients. However, it remains unclear what extent the bioengineered cardiac tissue 
contraction directly contribute to heart contraction when in transplantation. Recent reports has suggested that 
the bioengineered human embryonic stem cell/iPS cell-derived cardiac tissues using fibrin and collagen showed 
tensile strength around 0.1–11.8 mN/mm 2 in vitro11,12. However, because it has been reported that papillary 
muscle from human left ventricle shows around 40–50 mN/mm 2 of contractile force13, further development 
to promote cardiomyocyte maturation will be necessary to sufficiently support the injured left ventricle upon 
transplantation of bioengineered cardiac tissues in terms of tensile strength. On the other hand, the pressure 
changes are one of the important parameters to estimate the function of bioengineered cardiac tissues and the 
development of bioengineered pump will be applicable to support systemic circulation in heart failure patients. In 
the present study, tubular cardiac tissues around IVC demonstrated not only pulsation-mediated inner pressure 
changes in vivo, but also pressure changes that were comparable to a fundamental property of heart tissues to 
response to pressure load accompanied with an impulse-conducting system. They produced 9.1 mmHg of inner 
pressure changes at most at 8 weeks after transplantation. Although that maximum inner pressure change is not 
fully sufficient to support systemic circulation, it might be applicable to support pulmonary circulation. In other 
Figure 2. Transplantation of cardiac cell sheets around the inferior vena cava (IVC). (a) Representative 
macroscopic image of a monolayer cell sheet. (b) Schematic illustration of transplantation of two pairs of 
triple-layered cardiac cell sheets around the IVC. (c) Macroscopic image of cardiac cell sheet transplantation 
around the IVC. The area surrounded by white dots indicates the transplanted cardiac cell sheets around the 
IVC. (d) Schematic illustration of the time course of transplantation and analysis. (e) Representative image 
of echographic analysis at 4 weeks after transplantation. The area surrounded by white dots indicates the 
transplanted tissues around the IVC. Ao: Aorta. Bars, 1 mm. (f) Echographic analysis of the transplanted tissue 
thickness 2–8 weeks after transplantation (n = 4). *p < 0.05. All data are represented as means ± SD.
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words, tubular cardiac tissues could be applied to the Fontan conduit to support Fontan circulation. Because 
blood flow from the IVC to pulmonary artery is regulated by only central venous pressure in Fontan circulation, 
it is difficult for patients with pulmonary hypertension to be treated by the Fontan operation. Although further 
development of tissue fabrication by cell sheet transplantation on conduits with valves that enable to assist unidi-
rectional blood flow is necessary, tubular cardiac tissues will be able to function as a pulmonary ventricle.
It is well known that pluripotent stem cell-derived cardiomyocytes have immature fetal phenotypes. iPS 
cell-derived cardiomyocytes have been reported to become mature to some extent over time in vitro and in vivo14. 
In the present study, the mRNA expression of several cardiac contractile genes and a ryanodine receptor in trans-
planted cardiac tissues was significantly upregulated over time in vivo compared with that in cardiomyocytes 
in vitro. Because the ryanodine receptor is indispensable for calcium-induced calcium release15, upregulation of 
Figure 3. Immunohistochemical analysis of transplanted tissues. (a) Hematoxylin-eosin staining of 
transplanted tissues at 4 weeks. CM and Int. indicate cardiomyocyte and interstitial layer, respectively. Bars, 
500 μ m. (b–e) Immunofluorescence analysis of transplanted tissues around the IVC at 4 weeks. (b) Cardiac 
troponin T (cTnT)-positive cells (red). Nuclei were stained with 4′ , 6-diamidino-2-phenylindole (DAPI). Bars, 
500 μ m. (c) Connexin 43 (green, arrow heads) expression in the graft area (red). Nuclei were stained with DAPI. 
Bars, 20 μ m. (d) von Willebrand factor (vWF)-positive microvascular networks (green) in cTnT-positive cardiac 
tissues (red). Nuclei were stained with DAPI. Bars: 50 μ m. (e) Human mitochondria (red) in transplanted 
cardiac tissues (green). Area between the white lines indicates the transplanted tissues. Nuclei were stained with 
DAPI. Bars, 100 μ m.
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the ryanodine receptor might strengthen the function of bioengineered cardiac tissues. Moreover, we compared 
the expression of cardiac genes in tissues transplanted around the IVC and abdominal aorta. Because chronic 
stretch conditions have been reported to induce cardiomyocyte maturation10, cardiac gene expression was 
expected to be upregulated in cardiac tissues around the aorta compared with those around the IVC. However, as 
shown in Fig. 6, there were no differences between the cardiac gene expression of cardiac tissues around the IVC 
and aorta. Because the rat heart rate was around 300–400 beats per minute, the transplanted tissues around the 
aorta were supposed to be exposed to a high stretch frequency. Human iPS cell-derived cardiomyocytes might 
not tolerant excess rapid pulsation. Therefore, the aorta pulsation might not be effective for maturation of trans-
planted human cardiac tissues.
There are some limitations in this study. Although cardiac tissues pulsation around the IVC generated inner 
pressure changes notably, they were recorded in a closed environment and not in an unclamped condition. Also, 
we observed big variations of inner pressure changes among samples (Fig. 5e,f), which might lead to fail to show 
the statistical differences on the inner pressure changes between 4 and 8 weeks in spite of the significant difference 
of several cardiac contractile gene expression. We suppose that the difference of the engraftment and thickness 
of transplanted cardiac tissues among samples (Supplementary Fig. 4) might be one of the reasons for those 
issues. We transplanted two pairs of triple-layered cardiac cell sheets and used the hemodynamics data on ani-
mals in which the graft pulsation was observed in echography. However, the engraftment and tissue thickness in 
those animals were different. Although we observed CD31-positive endothelial cells in cardiac cell sheets before 
transplantation, the number of them was quite low and microvascular network derived from CD31-positive 
endothelial cells was not observed in cardiac cell sheets in vitro. The microvascular network in cell sheets before 
transplantation has been reported to be indispensable for further engraftment and subsequent improvement of 
cardiac function in rat myocardial infarction model16. In addition, as shown in Supplementary Fig. 2, endothelial 
cells in the transplanted cardiac tissues were mainly derived from host rat, but not human. Therefore, the cardiac 
tissues might be exposed to the ischemic condition for a while after the transplantation until the sufficient micro-
vasculature was established in the cardiac tissues, which might lead to less engraftment. We previously reported 
that step-wise cell sheet layering of pre-vascularized cell sheets17 on suitable vascular beds enabled fabrication of 
multi-layered thickened and dense cardiac tissues in vivo18, ex vivo19, and in vitro20 by inducing microvascular 
network formation in tissues. Because tubular cardiac tissues with approximately 500-μ m thickness generated 
pressure of 9.1 mmHg in a closed environment, fabrication of thicker cardiac tissues through these technologies 
might enable to generate pressure more efficiently in an unclamped condition. We suppose that the cardiomyo-
cyte disalignment in cardiac cell sheets might be another reason for issues in this study. It is widely known that 
cardiomyocytes in hearts show well-ordered alignment, which contributes to generate cardiac output efficiently. 
However, as shown in Fig. 1d and e, the alignment of cardiomyocytes in cell sheets before transplantation was 
irregular. Recently several groups including us have reported the strategies to promote cell alignment using some 
micropatterned surfaces21,22. The application of such technologies will provide us the well aligned cardiac tissues 
to generate inner pressure changes more efficiently with less variation.
In conclusion, we showed the possibility of human bioengineered cardiac tissues as a pulsatile bioengineered 
pump in vivo, which might lead to the development of a new type of heart assist devise. In addition to method-
ological advancement to reduce the risk of tumor formation upon transplantation of iPS cell-derived tissues, 
further development of tissue fabrication by cell sheet transplantation on conduits with valves in large animal 
models may provide us with a new therapeutic strategy for heart failure.
Methods
Antibodies and regents. The following antibodies were used for flow cytometry and immunocytochem-
istry: isotype IgG1 mouse monoclonal antibody (Dako, Glostrup, Denmark), anti-cTnT mouse monoclonal 
antibody (Thermo Scientific, Rockford, IL), anti-SM22 rabbit polyclonal antibody (Abcam, Cambridge, UK), 
anti-α smooth muscle actin (α SMA) rabbit polyclonal antibody (Abcam), anti-CD31 rabbit polyclonal anti-
body (Neomarkers, Fremont, CA), anti-connexin 43 rabbit polyclonal antibody (Abcam), anti-vWF rabbit poly-
clonal antibody (Abcam), anti-human mitochondria mouse monoclonal antibody (Merck Millipore, Darmstadt, 
Germany), anti-collagen 1 rabbit polyclonal antibody (Abcam), and anti-vimentin rabbit polyclonal antibody 
(Abcam). Secondary antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA).
Cardiac differentiation of hiPS cells, cardiomyocyte purification, and cardiac cell sheet preparation. 
Human iPS cell line 201B7 was purchased from RIKEN (Tsukuba, Japan). iPS cells were maintained in Primate 
ES Cell Medium (ReproCELL, Yokohama, Japan) supplemented with 5 ng/ml basic fibroblast growth factor 
Figure 4. Flow diagram of study population. 
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(ReproCELL) on mitomycin C-treated mouse embryonic fibroblasts (ReproCELL) at 37 °C in a humidified 
atmosphere with 5% CO2. Cells were passaged as small clumps every 3–4 days using CTK solution (ReproCELL). 
To purify cardiomyocytes after the cardiac differentiation, we established iPS cell line that expressed the 
puromycin-resistance gene under the control of the mouse α -MHC promoter and the neomycin-resistance gene 
under the control of the rex-1 promoter as described previously23,24. Briefly a lentiviral vector (α -MHC-pure 
rex-1-neo) containing the puromycin-resistance gene under the control of the mouse α -MHC promoter and the 
neomycin-resistance gene under the control of the rex-1 promoter was purchased from Addgene (Cambridge, 
MA) and transduced into human iPS cells. Only undifferentiated cells expressed the recombinant gene induced 
by G418 sulfate (Thermo Scientific) for cell expansion. Differentiated cardiomyocytes could be purified by puro-
mycin treatment.
The cardiac differentiation protocol in the bioreactor system (ABLE Co., Tokyo, Japan) has been described 
previously5. Briefly, at 2 days after starting the culture in the bioreactor system with mTeSR1, EBs were cultured in 
StemPro34 medium containing 50 μ g/ml ascorbic acid (Sigma-Aldrich, St. Louis, MO), 2 mM L-glutamine (Life 
Technologies), and 400 μ M 1-thioglycerol (Sigma-Aldrich). The cells were then treated with 0.5 ng/ml bone mor-
phogenic protein-4 (R&D systems, Minneapolis, MN) (days 0–1), 10 ng/ml bone morphogenic protein-4 (days 
1–4), 5 ng/ml bFGF (days 1–4), 3 ng/ml activin A (R&D Systems) (days 1–4), 4 μ M IWR-1 (Wako, Osaka, Japan) 
(days 4–6), 5 ng/ml vascular endothelial growth factor (R&D Systems) (days 6–16), and 10 ng/ml bFGF (days 
6–16). On day 16 of cardiac differentiation, after cells were dissociated with 0.05% trypsin/EDTA, single cells 
Figure 5. Physiological analysis of tubular cardiac tissues around the IVC. At 4 and 8 weeks after 
transplantation, rats were intubated and attached to an artificial ventilator under anesthesia. The pressure 
catheter was inserted into the right femoral vein and the head of the catheter was positioned just into the 
transplanted cardiac tissue. Pressure measurements were performed under the apnea by turning off the artificial 
ventilator. (a,b) The inner pressure changes evaluation of the transplanted tissue spontaneous pulsation without 
clamping IVC lumen. (a) Schematic illustration of the experiment. (b) Pulsation-mediated inner pressure 
changes before clamping the proximal and distal region of transplanted site in each experiment. (4 weeks, 
0–0.19 mmHg, n = 6; 8 weeks, 0.09–1.06 mmHg, n = 4, p = 0.08). Pressure measurements were performed under 
spontaneous beating. The data include pacing failure cases and pressure control failure case. Bars indicate the 
median value. (c-g) The inner pressure changes evaluation of the transplanted tissue pulsation with clamping 
IVC lumen and the electrical stimulation. (c) Schematic illustration of the experiment on the clamping site 
and the electrical stimulation. In order to change basal inner pressure of IVC, the proximal side of IVC was 
tightly clamped with an atraumatic bulldog clamp and the distal side of IVC was ligated with 6–0 silk with 
varying degree. (d) Representative images of the rat electrocardiogram (ECG) (upper), graft electrical potential 
(middle), and IVC inner pressure (lower) at 4 weeks. The data under the electrical stimulation at 0 (left), 60 
(middle) and 120 (right) pulses per minute (ppm). (e,f) Relationship between graft pulsation-mediated inner 
pressure changes and basal inner pressure of the IVC after clamping. Pressure measurements were performed 
under electrical stimulation at 80 ppm. (e) 4 weeks (n = 4). (f) 8 weeks (n = 3). (g) Maximum graft pulsation-
mediated inner pressure changes in each experiment were calculated and shown in the graph (4 weeks, n = 4; 8 
weeks, n = 3, p = 0.44). All data are represented as means ± SEM.
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were plated onto dishes in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (FBS) at 37 °C in a humidified atmosphere with 5% CO2. At 5 days after starting culture on 
dishes (day 21), cells were treated with puromycin (Thermo Scientific, 1.5 mg/mL) for 1 day. On the following day, 
remaining cells were dissociated with 0.05% trypsin/EDTA and re-seeded onto 35-mm temperature-responsive 
dishes (UpCell; CellSeed, Tokyo, Japan) at 2.1 × 105 cells/cm2 in DMEM supplemented with 10% FBS until the 
harvest of cell sheets (from day 22 to days 27–30). On days 27–30, cells were harvested as monolayer cardiac cell 
sheets by lowering the culture temperature to 20 °C.
Flow cytometry. Cells on days 21 and 27 of differentiation were dissociated with 0.05% trypsin/EDTA and 
fixed with 4% paraformaldehyde for 10 minutes. Fixed cells were stained with an isotype IgG1 or anti-cTnT anti-
bodies as described previously5. Stained cells were analyzed using a Gallios (Beckman Coulter, Brea, CA) and 
Kaluza software (Beckman Coulter).
Immunocytochemistry. Cells cultured on 24-well plates were fixed with 4% paraformaldehyde and stained 
with antibodies as described previously5. Samples were imaged by ImageXpress (Molecular Devices, Sunnyvale, 
CA) with MetaXpress and AcuityXpress software (Molecular Devices).
Transplantation procedure. All animal experiments were approved by the Ethics Committee for Animal 
Experimentation of Tokyo Women’s Medical University and performed according to the “Guide for the care 
and Use of Laboratory Animals” published by the US National Institutes of Health (NIH publication No. 85–23, 
revised 2011).
Monolayer cardiac cell sheets detached from the UpCell after culture at 20 °C for 30 minutes were stacked 
as a triple-layered sheets. The IVC of > 16-week-old nude rats was exposed by the abdominal median approach 
under 2% isoflurane anesthesia. A two pieces of triple-layered cardiac cell sheets were wrapped around the IVC 
to fabricate tubular cardiac tissues. The IVC with cardiac cell sheets was returned to the retroperitoneum space 
by approximating retroperitoneum with 5–0 absorbable sutures. The abdominal cavity was closed with 5–0 nylon 
sutures. Thirteen rats were transplanted with cardiac cell sheets and assigned 4-week and 8-week groups.
Echography. From 2 weeks after transplantation, rats were subjected to abdominal echography every week 
using the Vevo 2100 System (FUJIFILM VisualSonics, Toronto, Canada) under 2% isoflurane anesthesia. The 
thickness of the transplanted cardiac tissues was measured at the same position in individual rats up to 8 weeks 
after transplantation.
Pressure and electrical potential measurements. At 4 and 8 weeks after transplantation, rats were 
intubated and attached to an artificial ventilator under 2% isoflurane anesthesia. Two electrodes were attached to 
the right shoulder and left leg of rats to record the host electrocardiogram. The pressure catheter (1.4Fr; Millar, 
Houston, TX) was inserted into the right femoral vein and the head of the catheter was positioned just into the 
Figure 6. Quantitative polymerase chain reaction analysis of cardiac gene expression in cardiac tissues. 
Y-axis indicates relative gene expression compared with the cardiac cell sheet before transplantation. In vitro, 
cardiac cells from the same preparation of cell sheets were cultured for a further 4 weeks in vitro (n = 4). In vivo 
V, cardiac tissues around the IVC (n = 3). In vivo Ao, cardiac tissues around the abdominal aorta (n = 3). All 
data are represented as means ± SD. *p < 0.05; **p < 0.01.
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transplanted cardiac tissue. After the transplantation site was opened, two electrodes fashioned into a fishhook 
shape were attached to record the electrical potentials of the transplanted cardiac tissue and another two elec-
trodes were attached for electrical stimulation. To change inner pressure, blood flow was cut off by an atraumatic 
bulldog clamp at the proximal side of the IVC, and the tightness of clenching by 6–0 silk was modulated at the 
distal side. Pressure measurements were performed under the apnea by turning off the artificial ventilator. After 
measurements, rats were sacrificed and transplanted cardiac tissues were resected. PowerLab (ADInstruments, 
New South Wales, Australia) and LabChart 7 (ADInstruments) were used for recording and analysis.
Histology and immunohistochemical staining. At 4 and 8 weeks after transplantation, rats were sacri-
ficed and transplanted cardiac tissues were removed. Samples were fixed with 4% paraformaldehyde for a few days 
and routinely processed into 6-μ m-thick frozen sections. Hematoxylin-eosin staining was performed according 
to standard procedures. Immunohistochemical staining was performed with antibodies as described previously9. 
Samples were imaged using an Eclipse E800 optical microscope (Nikon, Tokyo, Japan) or confocal laser scanning 
microscope (LSM 510; Carl Zeiss, Jena, Germany) with ZEN software (Carl Zeiss).
Laser microdissection. A triple-layered cardiac cell sheet was wrapped around the IVC and abdominal 
aorta of 14-week-old nude rats. After the rats were sacrificed, transplanted cardiac tissues were removed and 
frozen quickly at 4 and 8 weeks after transplantation. Samples were routinely processed into 20-μ m-thick fro-
zen sections by a cryostat and fixed with 70% ethanol for 2 minutes. Then, cresyl violet staining was performed. 
Cardiomyocytes in serial sections were identified by immunofluorescence staining with the anti-cTnT antibody. 
Then, samples harvested by laser microdissection using a PALM MicroBeam (Carl Zeiss).
Real-time reverse transcription-polymerase chain reaction (PCR). Total RNA was isolated using 
an RNeasy Micro Kit (QIAGEN, Venlo, the Netherlands). cDNA was synthesized using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Stockholm, Sweden) with random hexamer primers. Real-time 
PCR analysis of each sample was then performed with a StepOne and StepOnePlus RealTime PCR System 
(Applied Biosystems). TaqMan assays for real-time PCR (Applied Biosystems) are listed in Supplementary Table 1. 
The average copy number of gene transcripts was normalized to that of glyceraldehyde-3-phosphate dehydroge-
nase for each sample.
Statistical analysis. Statistical analysis was performed with the Student’s t-test or paired t-test. For mul-
tiple comparisons of mRNA expression changes over time in vivo, the Tukey-Kramer test was performed after 
single-factor analysis of variance. P < 0.05 was considered significant. Data are expressed as the mean ± standard 
deviation except the pressure change expressed as the mean ± standard error.
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